Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoTrimResist: Cotrimoxazole Preventive Therapy Duration in HIV
NCT03087890Phase 4Completed
- Sponsor
- University of Bergen
- Start
- Mar 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Pneumocystis jirovecii pneumonia (PJP) and opportunistic infections (OIs) comparing Cotrimoxazole with Placebo (2 arms). Primary endpoint: Change in carriage of resistant bacteria in gut and/or nose at 48 weeks. Started Mar 2017; status: completed.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
Pneumocystis jirovecii pneumonia (PJP)opportunistic infections (OIs)
Beyond the preview
Go deeper on NCT03087890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087890.